3,5,3'-TRIIODOTHYRONINE RECEPTOR LIGANDS

Use of a compound seledod from the group consisting of 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzof-ur 3-yl)methanol hydrochloride (001), 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylaminoethoxy)-benzoyl)benzofuran hydrochloride (003), 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)benzofuran (005), 2methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofur-aa (011), 2-methyl-3-(3,5-diiodo-4-carboxyinethoxybenzyl)benzofuran (015), 4'hydroxy-3'-iodo-3,5-diiodo-4-(2-N,N-dimethy-laminodhoxy)benzophenon hydrochloride (024), 2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran (029), 4',4-dihydroxy-3'3,5-trii-odo.diphenylmethan (032), which compound is a 3,5,3'-triiodothymnine (T3) receptor tigand, for the preparation of a medicament for the therapeutic or prophylactic treatment of a disorder which depends on the expression of T-3 regulated genes, and pharmaoeutical preparations comprising said compounds, are disclosed. Further, a method of prophylactically or therapeutically treating a patient having a disorder which depends on the expression of 3,5,3'triiodo-thyronine (T-3) regulated genes is also dis-closed. The invention additionally comprises product protection for all the above listed compounds, except the compound (011).